Home > > > > > Report Detail

Global Osteoporosis Market, Patients, Companies & Forecast

Publisher Name :
Date: 24-Sep-2015
No. of pages: 124
Inquire Before Buying

Osteoporosis is a silent disease until it is complicated by fractures that occur following minimal trauma or, in some cases, with no trauma. Globally Osteoporosis is expected to be more than US$ 40 Billion market by 2019. China and India together have close to 80% of osteoporosis patients worldwide. Whereas this in case of hip fracture cases both the countries China and India have more than 60% patients. But when we study Osteoporosis in market terms then United States controls the highest market share followed by China and Japan. Amgen and Eli Lilly are two dominant players in Osteoporosis drugs market.

This is the 2nd edition report on Osteoporosis by Renub Research. Report titled “Global Osteoporosis Market, Patients, Companies & Forecast” provides a comprehensive analysis of the current state of this market and likely future evolution over the next 5 years. This 124 page report with 89 Figures and 8 Tables studies the Worldwide Osteoporosis market from 6 view points:


  • Osteoporosis Patients & Forecast

  • Hip fracture Patients & Forecast

  • Osteoporosis Market & Forecast

  • Country Wise Osteoporosis level of Awareness, Guidelines & Policy

  • Country Wise Reimbursement of Medication

  • Company Wise Osteoporosis Drugs Sales & Forecast  


All the 10 Countries studied in the report are as follows


  • India

  • China

  • Japan

  • Korea

  • Brazil

  • Russia

  • United Kingdom

  • France

  • Germany

  • United States


Worldwide Osteoporosis – Company Wise Drugs Sales Analysis (2010 – 2019)


  • Merck

  • Sanofi

  • Novartis

  • Eli Lilly

  • Amgen

Global Osteoporosis Market, Patients, Companies & Forecast

Table of Contents

1. Executive Summary

2. Worldwide Osteoporosis Patients Population Analysis
2.1 Worldwide Osteoporosis Patients Population (2010 – 2019)
2.2 Worldwide Hip Fracture Patients Population (2010 – 2019)

3. Worldwide Osteoporosis Market (2010 – 2019)

4. Worldwide Osteoporosis Share Analysis
4.1 Worldwide Osteoporosis Patients Population Share (2010 – 2019)
4.2 Worldwide Hip Fracture Patients Population Share (2010 – 2019)
4.3 Worldwide Osteoporosis Market Share (2010 – 2019)
4.4 Worldwide Osteoporosis Drugs Company Market Share (2010 –   2019)

5. India
5.1 India Osteoporosis Patients Population (2010 – 2019)
5.2 India Hip Fracture Patients Population (2010 – 2019)
5.3 India Osteoporosis Market (2010 – 2019)
5.4 Level of Awareness
5.5 Fracture Registries
5.6 Government Policies
5.7 Guidelines
5.8 Reimbursement of Medication

6. China
6.1 China Osteoporosis Patients Population (2010 – 2019)
6.2 China Hip Fracture Patients Population (2010 – 2019)
6.3 China Osteoporosis Market (2010 – 2019)
6.4 Level of Awareness
6.5 Fracture Registries
6.6 Government Policies
6.7 Guidelines
6.8 Reimbursement of Medication

7. Japan
7.1 Japan Osteoporosis Patients Population (2010 – 2019)
7.2 Japan Hip Fracture Patients Population (2010 – 2019)
7.3 Japan Osteoporosis Market (2010 – 2019)
7.4 Level of Awareness
7.5 Fracture Registries
7.6 Government Policies
7.7 Guidelines
7.8 Reimbursement of Medication

8. Korea
8.1 Korea Osteoporosis Patients Population (2010 – 2019)
8.2 Korea Hip Fracture Patients Population (2010 – 2019)
8.3 Korea Osteoporosis Market (2010 – 2019)
8.4 Level of Awareness
8.5 Fracture Registries
8.6 Government Policies
8.7 Guidelines
8.8 Reimbursement of Medication

9. Brazil
9.1 Brazil Osteoporosis Patients Population (2010 – 2019)
9.2 Brazil Hip Fracture Patients Population (2010 – 2019)
9.3 Brazil Osteoporosis Market (2010 – 2019)
9.4 Level of Awareness
9.5 Guidelines & Policy
9.6 Reimbursement Policy

10. Russia
10.1 Russia Osteoporosis Patients Population (2010 – 2019)
10.2 Russia Hip Fracture Patients Population (2010 – 2019)
10.3 Russia Osteoporosis Market (2010 – 2019)
10.4 Level of Awareness
10.5 Government Policy
10.6 Guidelines
10.7 Reimbursement

11. United Kingdom
11.1 United Kingdom Osteoporosis Patients Population (2010 – 2019)
11.2 United Kingdom Hip Fracture Patients Population (2010 – 2019)
11.3 United Kingdom Osteoporosis Market (2010 – 2019)
11.4 Guidelines
11.5 Reimbursement Policy

12. France
12.1 France Osteoporosis Patients Population (2010 – 2019)
12.2 France Hip Fracture Patients Population (2010 – 2019)
12.3 France Osteoporosis Market (2010 – 2019)
12.4 Guidelines
12.5 Reimbursement Policy

13. Germany
13.1 Germany Osteoporosis Patients Population (2010 – 2019)
13.2 Germany Hip Fracture Patients Population (2010 – 2019)
13.3 Germany Osteoporosis Market (2010 – 2019)
13.4 Guidelines
13.5 Reimbursement Policy

14. United States
14.1 United States Osteoporosis Patients Population (2010 – 2019)
14.2 United States Hip Fracture Patients Population (2010 – 2019)
14.3 United States Osteoporosis Market (2010 – 2019)
14.4 Policy
14.5 Guidelines
14.6 Reimbursement Policy

15. Growth Driver
15.1 Widespread Vitamin D Deficiency & Low Calcium Intake
15.2 Globally Increasing Ageing Population & Life Expectancy

16. Challenges
16.1 Lack of Reimbursement / Other Restrictions for Reimbursement
16.2 Limited Access of Diagnostic Tools & Low Levels of Public and Health Professional Awareness
16.3 Lack of Government Osteoporosis Policy, Guidelines & National Health Priority in Asia Pacific Countries

17. Key Players Osteoporosis Drugs Sales & Forecast
17.1 Merck Osteoporosis Drugs Sales (2010 – 2019)
17.2 Sanofi Osteoporosis Drugs Sales (2010 – 2019)
17.3 Novartis Osteoporosis Drugs Sales (2010 – 2019)
17.4 Eli Lilly Osteoporosis Drugs Sales (2010 – 2019)
17.5 Amgen Osteoporosis Drugs Sales (2010 – 2019)

List of Tables

Table 5–1: India – Osteoporosis Treatments & Respective Reimbursement Status, 2013
Table 6–1: China – Osteoporosis Treatments & Respective Reimbursement Status, 2013
Table 7–1: Japan – Osteoporosis Treatments & Respective Reimbursement, 2013
Table 8–1: Korea – Osteoporosis Treatments & Respective Reimbursement, 2013
Table 11–1: United Kingdom – Available Medical Interventions & Reimbursement Policies, 2013
Table 12–1: France – Available Medical Interventions & Reimbursement Policies, 2013
Table 13–1: Germany – Available Medical Interventions & Reimbursement Policies, 2013\
Table 16–1: Asia Pacific – Status of Osteoporosis in NHP & Guidelines Availability, 2013

List of Figures

Figure 2–1: Worldwide – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 2–2: Worldwide – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 2–3: Worldwide – Distribution of Hip Fracture Risk in Men, 2012
Figure 2–4: Worldwide – Distribution of Hip Fracture Risk in Women, 2012
Figure 2–5: Worldwide – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 2–6: Worldwide – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 3–1: Worldwide – Osteoporosis Market (Million US$), 2010 – 2014
Figure 3–2: Worldwide – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 4–1: Worldwide – Osteoporosis Patients Population Share (Percent), 2010 – 2014
Figure 4–2: Worldwide – Forecast for Osteoporosis Patients Population Share (Percent), 2015 – 2019
Figure 4–3: Worldwide – Hip Fracture Patients Population Share (Percent), 2010 – 2014
Figure 4–4: Worldwide – Forecast for Hip Fracture Patients Population Share (Percent), 2015 – 2019
Figure 4–5: Worldwide – Osteoporosis Market Share (Percent), 2010 – 2014
Figure 4–6: Worldwide – Forecast for Osteoporosis Market Share (Percent), 2015 – 2019
Figure 4–7: Worldwide – Osteoporosis Drugs Company Market Share (Percent), 2010 – 2014
Figure 4–8: Worldwide – Forecast for Osteoporosis Drugs Company Market Share (Percent), 2015 – 2019
Figure 5–1: India – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 5–2: India – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 5–3: India – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 5–4: India – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 5–5: India – Osteoporosis Market (Million US$), 2010 – 2014
Figure 5–6: India – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 6–1: China – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 6–2: China – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 6–3: China – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 6–4: China – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 6–5: China – Osteoporosis Market (Million US$), 2010 – 2014
Figure 6–6: China – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 7–1: Japan – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 7–2: Japan – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 7–3: Japan – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 7–4: Japan – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 7–5: Japan – Osteoporosis Market (Million US$), 2010 – 2014
Figure 7–6: Japan – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 8–1: Korea – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 8–2: Korea – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 8–3: Korea – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 8–4: Korea – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 8–5: Korea – Osteoporosis Market (Million US$), 2010 – 2014
Figure 8–6: Korea – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 9–1: Brazil – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 9–2: Brazil – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 9–3: Brazil – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 9–4: Brazil – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 9–5: Brazil – Osteoporosis Market (Million US$), 2010 – 2014
Figure 9–6: Brazil – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 10–1: Russia – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 10–2: Russia – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 10–3: Russia – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 10–4: Russia – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 10–5: Russia – Osteoporosis Market (Million US$), 2010 – 2014
Figure 10–6: Russia – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 10–7: Russia – Level of Awareness (Percent), 2010
Figure 11–1: United Kingdom – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 11–2: United Kingdom – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019.
Figure 11–3: United Kingdom – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 11–4: United Kingdom – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 11–5: United Kingdom – Osteoporosis Market (Million US$), 2010 – 2014
Figure 11–6: United Kingdom – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 12–1: France – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 12–2: France – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 12–3: France – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 12–4: France – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 12–5: France – Osteoporosis Market (Million US$), 2010 – 2014
Figure 12–6: France – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 13–1: Germany – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 13–2: Germany – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 13–3: Germany – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 13–4: Germany – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 13–5: Germany – Osteoporosis Market (Million US$), 2010 – 2014
Figure 13–6: Germany – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 14–1: United States – Osteoporosis Patients Population (Thousand), 2010 – 2014
Figure 14–2: United States – Forecast for Osteoporosis Patients Population (Thousand), 2015 – 2019
Figure 14–3: United States – Hip Fracture Patients Population (Thousand), 2010 – 2014
Figure 14–4: United States – Forecast for Hip Fracture Patients Population (Thousand), 2015 – 2019
Figure 14–5: United States – Osteoporosis Market (Million US$), 2010 – 2014
Figure 14–6: United States – Forecast for Osteoporosis Market (Million US$), 2015 – 2019
Figure 15–1: Worldwide – Ageing Population & Forecast (Million), 2010 – 2050
Figure 15–2: Worldwide – Life Expectancy (Year), 1990, 2000 & 2012
Figure 17–1: Merck – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–2: Merck – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–3: Sanofi – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–4: Sanofi – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–5: Novartis – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–6: Novartis – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–7: Eli Lilly – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–8: Eli Lilly – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019
Figure 17–9: Amgen – Osteoporosis Drugs Sales (Million US$), 2010 – 2014
Figure 17–10: Amgen – Forecast for Osteoporosis Drugs Sales (Million US$), 2015 – 2019

  • Global Osteoporosis Drugs Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 89
    According to our LPI (LP Information) latest study, the global Osteoporosis Drugs market size was valued at US$ million in 2023. With growing demand in downstream market, the Osteoporosis Drugs is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Osteoporosis Drugs market. Osteoporosis Drugs are expected to show stable growth in the future market. However, product differentiation, r......
  • Global Alendronate Sodium Market Research Report 2023, Forecast to 2028
    Published: 27-Dec-2023        Price: US 2680 Onwards        Pages: 130
    Alendronate sodium is used to prevent and treat osteoporosis. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios......
  • Global Alendronate Sodium Professional Survey Report 2023, Forecast to 2028
    Published: 27-Dec-2023        Price: US 3280 Onwards        Pages: 101
    Alendronate sodium is used to prevent and treat osteoporosis. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios......
  • Osteoporosis Drugs Industry Forecasts - China Focus
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 93
    This study focuses on China's Osteoporosis Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. ......
  • Osteoporosis Drugs Companies in China
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 67
    This study focuses on China's Osteoporosis Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions ......
  • Osteoporosis Drugs Markets in China
    Published: 27-Nov-2023        Price: US 4000 Onwards        Pages: 205
    China's demand for Osteoporosis Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, in......
  • Global Osteoporosis Drugs Market Research Report 2023, Forecast to 2028
    Published: 17-Nov-2023        Price: US 2680 Onwards        Pages: 139
    Bisphosphonates are usually the first choice for osteoporosis treatment. These include: Alendronate (Fosamax), a weekly pill. Risedronate (Actonel), a weekly or monthly pill. Ibandronate (Boniva), a monthly pill or quarterly intravenous (IV) infusion. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, ......
  • Global Risedronate Sodium Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 09-Nov-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Risedronate Sodium market: According to our latest research, the global Risedronate Sodium market looks promising in the next 5 years. As of 2022, the global Risedronate Sodium market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Risedronate Sodiu......
  • Global Raloxifene Hydrochloride Professional Survey Report 2023, Forecast to 2028
    Published: 07-Nov-2023        Price: US 3280 Onwards        Pages: 107
    Raloxifene Hydrochloride is the hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advanta......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs